Aktis Oncology, which recently had its IPO, has gained substantial backing from Big Pharma mainstay Eli Lilly. Investors should take note of the biotech firm.
BOSTON, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (“Aktis”), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large...
Akoustis Technologies files for Chapter 11 to facilitate a strategic sale while addressing legal issues with Qorvo.Quiver AI SummaryAkoustis Technologies, Inc. has announced that it has voluntarily filed...
For Immediate ReleaseChicago, IL – December 10, 2024 – Today, Zacks Equity Research discusses RF Industries RFIL and Akoustis Technologies AKTS.Industry: Radio-Frequency SemiconductorsLink: https://www.zacks.com/commentary/2380991/2-radio-frequency-stocks-to-watch-in-a-challenging-industryThe...
The Zacks Semiconductors - Radio Frequency industry participants are suffering from a challenging demand environment, primarily attributed to a suspension in capital spending by telecom carriers. Industry...
Akoustis Technologies, Inc. (NASDAQ: AKTS) shares were in the green Tuesday. The integrated device manufacturer ...